<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BR</journal-id>
<journal-title-group>
<journal-title>Biomedical Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9434</issn>
<issn pub-type="epub">2049-9442</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/br.2014.380</article-id>
<article-id pub-id-type="publisher-id">br-03-01-0055</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reversible posterior leukoencephalopathy syndrome secondary to systemic-onset juvenile idiopathic arthritis: A case report and review of the literature</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>PINGPING</given-names></name>
<xref rid="af1-br-03-01-0055" ref-type="aff">1</xref>
<xref rid="af2-br-03-01-0055" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>LI</surname><given-names>XIAOFENG</given-names></name>
<xref rid="af2-br-03-01-0055" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>LI</surname><given-names>YATING</given-names></name>
<xref rid="af2-br-03-01-0055" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>WANG</surname><given-names>JING</given-names></name>
<xref rid="af1-br-03-01-0055" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>ZENG</surname><given-names>HUASONG</given-names></name>
<xref rid="af1-br-03-01-0055" ref-type="aff">1</xref>
<xref ref-type="corresp" rid="c1-br-03-01-0055"/></contrib>
<contrib contrib-type="author"><name><surname>ZENG</surname><given-names>XIAOFENG</given-names></name>
<xref rid="af3-br-03-01-0055" ref-type="aff">3</xref></contrib>
</contrib-group>
<aff id="af1-br-03-01-0055">
<label>1</label>Department of Pediatrics, Allergy, Immunology and Rheumatology, Guangzhou Women and Children&#x0027;s Medical Center, Guangzhou Medical University and First Clinical Medical College, Jinan University, Guangzhou 510120, P.R. China</aff>
<aff id="af2-br-03-01-0055">
<label>2</label>Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, P.R. China</aff>
<aff id="af3-br-03-01-0055">
<label>3</label>Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China</aff>
<author-notes>
<corresp id="c1-br-03-01-0055"><italic>Correspondence to</italic>: Professor Huasong Zeng, Department of Pediatric, Allergy, Immunology and Rheumatology, Guangzhou Women and Children&#x0027;s Medicial Center, Guangzhou Medical University and First Clinical Medical College, Jinan University, 402 Renmin Road, Guangzhou 510120, P.R. China E-mail: <email>huasongz@126.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>01</month><year>2015</year></pub-date>
<pub-date pub-type="epub"><day>07</day><month>11</month><year>2014</year></pub-date>
<volume>3</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>58</lpage>
<history>
<date date-type="received"><day>09</day><month>09</month><year>2014</year></date>
<date date-type="accepted"><day>29</day><month>10</month><year>2014</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2015, Spandidos Publications</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<abstract>
<p>Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinical syndrome based on changes in clinical imaging, and it has been reported to mainly occur in adults. However, it has been recently discovered that RPLS is also prevalent in infant patients, particularly in those using glucocorticoids, immunosuppressant medications and cytotoxic drugs. The current study presents a 5-year-old male with a previous diagnosis of systemic-onset juvenile idiopathic arthritis (SoJIA) and macrophage-activation syndrome who developed posterior reversible encephalopathy syndrome during treatment with glucocorticoids, disease-modifying antirheumatic drugs and biological agent (etanercept) therapy. After &#x007E;5 days of treatment, the patient made a complete clinical recovery; the magnetic resonance imaging reviewed 2 weeks later showed that the previous hyper-intensity signal had disappeared and the multiple lesions in the brain had been completely absorbed. The case report shows that, conforming to recent literature, SoJIA in infants should be considered a risk factor for developing RPLS. The clinical manifestations of the disease are multiple, but usually reversible, and the patients mostly have a good prognosis. Rapid diagnosis and treatment is essential as early treatment may prevent progression to irreversible brain damage. By increasing the awareness of RPLS, the patient care may improve and further insight may be gained.</p>
</abstract>
<kwd-group>
<kwd>systemic-onset juvenile idiopathic arthritis</kwd>
<kwd>reversible posterior leukoencephalopathy syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently reported disorder present in a variety of clinical settings with characteristic findings in magnetic resonance imaging (MRI) exhibiting bilateral gray and white matter abnormalities in the posterior regions of the cerebral hemispheres and cerebellum (<xref rid="b1-br-03-01-0055" ref-type="bibr">1</xref>). This syndrome is characterized by acute to subacute onset of headache, nausea, dizziness, changes in consciousness (lethargy, coma, diminished spontaneity of speech), convulsions and transient visual disturbances [such as cortical blindness (<xref rid="b2-br-03-01-0055" ref-type="bibr">2</xref>)]. RPLS is caused by various heterogeneous factors and has been described in numerous medical conditions (<xref rid="b3-br-03-01-0055" ref-type="bibr">3</xref>). Hypertension and immunosuppressive or cytotoxic drugs have been reported to be the most significant causes of RPLS in pediatric and adult patients (<xref rid="b4-br-03-01-0055" ref-type="bibr">4</xref>,<xref rid="b5-br-03-01-0055" ref-type="bibr">5</xref>).</p>
<p>RPLS has been previously reported to mainly occur in adults, and is less frequent in children. However, it has been recently recognized that RPLS is also prevalent in child patients (<xref rid="b6-br-03-01-0055" ref-type="bibr">6</xref>), particularly in those with acute leukemia, autoimmune disease (such as Henoch-Sch&#x00F6;nlein purpura or systemic lupus erythematosus), sickle cell anemia and nephrotic syndrome, in which patients were mainly taking glucocorticoids, immunosuppressant medications, cytotoxic drugs or had severe hypertension. The current study presents a case report of RPLS in a 5-year-old Chinese male with systemic-onset juvenile idiopathic arthritis (SoJIA) who was hospitalized in Guangzhou Women and Children&#x0027;s Medical Center (Guangzhou, China).</p>
</sec>
<sec>
<title>Case report</title>
<p>The study reports the case of a 5-year-old male who presented primarily with repeated joint pain (hip and knee), remittent fever (&#x007E;2 weeks), unfixed rash and pericardial effusion. Written informed consent was obtained from the patient for publication and any accompanying images. The patient was diagnosed to have SoJIA following exclusion of infectious diseases, leukemia and tumor diseases. Subsequently, the patient received treatment of glucocorticoids, cyclosporine A (CsA), Methotrexate (MTX) and a biological agent (0.8 mg&#x002F;kg etanercept per week injected hypodermicly), and the condition gradually improved. The patient was infected by the measles virus during the treatment process, and recovered following treatment with intravenous immunoglobulin.</p>
<p>However, after &#x007E;2 months of treatment the patient suddenly presented with moderate hypertension, dizziness, apathia, diminished spontaneity of speech, exhibited consciousness changes and could only recognize his parents. Examination revealed severely impaired memory, dyscalculia and the ability of orientation decreased significantly. As opposed to certain other cases (<xref rid="b7-br-03-01-0055" ref-type="bibr">7</xref>,<xref rid="b8-br-03-01-0055" ref-type="bibr">8</xref>), the patient had no convulsion and visual loss, and the neurological physical examination was normal. There was no clinical or laboratory evidence of infection, and the serum electrolyte levels were normal. At that time, blood pressure was 137&#x002F;89 mmHg, the serum CsA level was 151.6 mg&#x002F;l (therapeutic range, 120&#x2013;200 mg&#x002F;l). Subsequently, the patient received an emergency antihypertensive drug and the treatment for dehydration to lower the intracraninal pressure. A lumbar puncture and MRI were performed in order to exclude intracranial infections and thromboembolic disease. No clear abnormalities were detected in the cerebrospinal fluid. Magnetic resonance angiography (MRA) and diffusion-weighted imaging of the head (<xref rid="f1-br-03-01-0055" ref-type="fig">Fig. 1</xref>) showed a diffusely abnormal signal in the parieto-occipital areas, left hippocampus and left dorsal thalamus, T1-weighted image (T1WI) showed a low signal and T2WI showed a high signal, all of which was suggestive of typical RPLS imaging changes. In addition, MRA also found that the bilateral posterior cerebral artery was slender (<xref rid="f1-br-03-01-0055" ref-type="fig">Fig. 1</xref>). By antihypertensive treatment, and discontinued CsA treatment, the condition improved gradually during the first 3 days of hospitalization, as the patient could recall his friends&#x0027; names and his speech was more fluent. All the symptoms disappeared completely on day 5 of hospitalization, and memory power, calculation ability and orientation ability of the patient had returned to premorbid levels, and the physical examination was normal with no discomfort. The MRI was reviewed 2 weeks later (<xref rid="f2-br-03-01-0055" ref-type="fig">Fig. 2</xref>) and showed that the previous hyper-intensity signal in T2WI had disappeared, the multiple lesions in the brain had been completely absorbed, whereas the posterior cerebral artery was as slender as before.</p>
<p>There have been over two months since the last MRI, and the patient regularly underwent a review in the outpatient department; blood pressure was controlled at &#x007E;110&#x002F;75 mmHg, and the current oral drugs included glucocorticoid, MTX and antihypertensive drugs, coupled with regular injections of biological agents. The patient currently has no discomfort and the condition remained stable.</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>RPLS was first reported in 1996 by Hinchey <italic>et al</italic> (<xref rid="b3-br-03-01-0055" ref-type="bibr">3</xref>), and represented a reversible, predominantly posterior leukoencephalopathy in patients that had renal insufficiency, hypertension or were maintained on immunosuppressants. RPLS is diagnosed based on the typical pattern of brain imaging and the reversibility of symptoms. With the recent wide-spread use of MRI in clinical practice, the relevant cases reported have increased every year; however, findings remain limited in pediatric patients. Radiographic lesions in posterior reversible encephalopathy syndrome (PRES) are rarely isolated to the &#x2018;posterior&#x2019; parieto-occipital white matter and often involve the cortex, frontal lobes, basal ganglia and brainstem (<xref rid="b9-br-03-01-0055" ref-type="bibr">9</xref>,<xref rid="b10-br-03-01-0055" ref-type="bibr">10</xref>). Although reversible by definition, if the patients did not undergo early recognition and timely treatment, irreversible brain damage may occur (<xref rid="b11-br-03-01-0055" ref-type="bibr">11</xref>), and therefore, the restricted term of posterior reversible leukoencephalopathy may not be appropriate as the condition is not always reversible, it is not necessarily confined to the posterior regions of the brain and it can affect white and grey matter (<xref rid="b12-br-03-01-0055" ref-type="bibr">12</xref>). Regarding this, Casey <italic>et al</italic> (<xref rid="b2-br-03-01-0055" ref-type="bibr">2</xref>) suggested referring to RPLS as PRES. RPLS, or PRES, is characterized by acute to subacute disorder of headache, nausea, dizziness, changes in consciousness, convulsions and transient visual disturbances. The clinical manifestation varies, but not all symptoms appear in the whole process, and certain symptoms may occur repeatedly. Due to the previously reported low incidence and clinical features of reversibility, RPLS did not obtain enough clinical attention, and the pathogenesis remains unknown. Currently, the majority of studies (<xref rid="b13-br-03-01-0055" ref-type="bibr">13</xref>&#x2013;<xref rid="b16-br-03-01-0055" ref-type="bibr">16</xref>) agree that RPLS usually occurs during the process of suddenly raised blood pressure or the use of certain drugs (including CsA, corticosteroids, other immunosuppressive and cytotoxic drugs). Abrupt hypertension contributes to the development of PRES, and the hyperperfusion theory is supported by the frequent presence of substantial hypertension in patients with PRES and subsequent resolution of clinical symptoms and radiological edema with prompt treatment of hypertension (<xref rid="b2-br-03-01-0055" ref-type="bibr">2</xref>).</p>
<p>However, clinicians should also be aware that certain cases transpire in the absence of severe hypertension, and infants also develop RPLS at lower absolute pressures compared to adults. Unless pressures are recorded frequently and compared to baseline values, gradual increases or transient spikes in blood pressure may be overlooked. This applies to young or pregnant patients in particular, with baseline pressures that are normally low (<xref rid="b9-br-03-01-0055" ref-type="bibr">9</xref>).</p>
<p>The pathophysiology of RPLS is complex, and there are various opinions on its pathogenesis (<xref rid="b3-br-03-01-0055" ref-type="bibr">3</xref>,<xref rid="b19-br-03-01-0055" ref-type="bibr">19</xref>&#x2013;<xref rid="b21-br-03-01-0055" ref-type="bibr">21</xref>). Hypertension, cytotoxic drugs or other causes of RPLS are considered to induce endothelial damage and breakdown in cerebral autoregulation, which lead to the movement of fluid from the intravascular into the pericapillary astrocytes, as well as into the interstitium through the capillary wall (<xref rid="b3-br-03-01-0055" ref-type="bibr">3</xref>,<xref rid="b21-br-03-01-0055" ref-type="bibr">21</xref>,<xref rid="b22-br-03-01-0055" ref-type="bibr">22</xref>). Immunosuppressive and cytotoxic drugs, by direct endothelial damage or through the inhibition of prostacyclin, disrupt the endothelial cell integrity, causing them to release endothelin (<xref rid="b23-br-03-01-0055" ref-type="bibr">23</xref>,<xref rid="b24-br-03-01-0055" ref-type="bibr">24</xref>), which causes vasoconstriction and vasospasm in cerebral vessels, initiates mild, reversible ischemia and white matter edema (<xref rid="b25-br-03-01-0055" ref-type="bibr">25</xref>,<xref rid="b26-br-03-01-0055" ref-type="bibr">26</xref>). Specific binding sites for endothelin have been identified in several areas of the human brain, including the cerebellum, hippocampal formation, diencephalon and choroid plexus (<xref rid="b25-br-03-01-0055" ref-type="bibr">25</xref>). Additionally, the cerebral white matter is composed of myelinated fibre tracts in a cellular matrix of glial cells, arterioles and capillaries, which make the structure more susceptible to the accumulation of fluid in the extracellular spaces (vasogenic oedema) (<xref rid="b27-br-03-01-0055" ref-type="bibr">27</xref>), and is possibly the reason for the prone involvement of brain white matter. Regional variations in sympathetic innervation of the vasculature of the central nervous system may account for the unique localization of these lesions in the posterior cerebral hemispheres (<xref rid="b2-br-03-01-0055" ref-type="bibr">2</xref>,<xref rid="b11-br-03-01-0055" ref-type="bibr">11</xref>). The study by Schwartz <italic>et al</italic> (<xref rid="b28-br-03-01-0055" ref-type="bibr">28</xref>) indicated that the vertebrobasilar system possesses sparse sympathetic innervation that may result in disruption of autoregulatory mechanisms, preferentially affecting the posterior lobes. Furthermore, glucocorticoids can also lead to increased blood pressure and endothelial dysfunction. In addition, previous studies (<xref rid="b29-br-03-01-0055" ref-type="bibr">29</xref>&#x2013;<xref rid="b31-br-03-01-0055" ref-type="bibr">31</xref>) have reported that biological agents and measles virus infection or measles vaccination also cause RPLS, although the specific mechanism is unclear.</p>
<p>Although the prognosis is usually good, not quickly recognizing the syndrome and discontinuing the treatment with the offending agent may result in profound and permanent central nervous system dysfunction or fatality. Therefore, more attention should be focused on RPLS, particularly in patients with associated diseases or risk factors, and if the patients have a sudden episode of neurological symptoms, MRI examination should be performed in sufficient time. Early recognition of PRES is important for prompt therapy, which typically consists of gradual blood pressure control and withdrawal of the potentially offending agents (<xref rid="b2-br-03-01-0055" ref-type="bibr">2</xref>), and of note, the MRI review following treatment is equally important for the diagnosis and treatment of this disease.</p>
<p>In a previous study, RPLS secondary to SoJIA has been reported in an infant with SoJIA during treatment with pulse methylprednisolone therapy (<xref rid="b31-br-03-01-0055" ref-type="bibr">31</xref>), however, in this case the infant was younger and did not receive pulse glucocorticoids therapy, previous measles virus infection and the application of CsA may be the possible factors leading to RPLS, although the blood CsA concentration was within normal limits when RPLS occurred in this patient. Similar to the study (<xref rid="b31-br-03-01-0055" ref-type="bibr">31</xref>), a sudden alteration in inflammatory milieu and&#x002F;or hypertension in differing degrees of severity appear to be common to all the different implicated causes of PRES. The blood of the patient also had moderate hypertension at the onset of RPLS, whereas normal blood pressure was exhibited at ordinary times. In addition, with such a diffuse lesion scope in the head MRI, the study postulated that an increased vascular permeability associated with vascular endothelial damage may be the pathogenesis of PRES in this case, whereas the narrow brain artery ring in the patient may be only a congenital dysplasia.</p>
<p>The present case report highlights that there is also a possibly important association of RPLS with SoJIA. The early clinical manifestation of RPLS is various, and there may be no convulsions and no visual disturbances, but only apathia, moderate hypertension, diminished spontaneity of speech and retards in response. Early recognition of RPLS as a complication during various diseases and therapies in childhood may facilitate precise diagnosis and appropriate treatment, suggesting a good prognosis. In the present case, previous measles virus infection and the applications of CsA were possible factors leading to RPLS. Prompt diagnosis and therapy with antihypertensives, removal of the offending medication and treatment of the associated disorders is essential, as early treatment may prevent progression to irreversible brain damage. With increased medical awareness of RPLS, the patient care may be improved and further insight into this complication may be gained through continued research.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank Dr Ying Xie and Dr Feng Li who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data. Guangzhou City Grant (China) provided funding to Professor Huasong Zeng (no. 2012J4100031) for design, collection and decision to submit the manuscript for publication. The National High Technology Research and Development Program 863 (China) provided funding to Professor Xiaofeng Zeng (no. 012AA02A513) for the data analysis and writing of the manuscript.</p>
</ack>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>SoJIA</term><def><p>systemic-onset juvenile idiopathic arthritis</p></def></def-item>
<def-item><term>RPLS</term><def><p>reversible posterior leukoencephalopathy syndrome</p></def></def-item>
<def-item><term>cyclosporine A</term><def><p>CsA</p></def></def-item>
<def-item><term>MTX</term><def><p>Methotrexate</p></def></def-item>
<def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item>
<def-item><term>PRES</term><def><p>posterior reversible encephalopathy syndrome</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-br-03-01-0055"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>A</given-names></name><name><surname>Fuchigami</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Posterior reversible encephalopathy syndrome in childhood: report of four cases and review of the literature</article-title><source>Pediatr Emerg Care</source><volume>28</volume><fpage>153</fpage><lpage>157</lpage><year>2012</year></element-citation></ref>
<ref id="b2-br-03-01-0055"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>SO</given-names></name><name><surname>Sampaio</surname><given-names>RC</given-names></name><name><surname>Michel</surname><given-names>E</given-names></name><etal/></person-group><article-title>Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortieal lesions</article-title><source>AJNR Am J Neuroradiol</source><volume>21</volume><fpage>1199</fpage><lpage>1260</lpage><year>2000</year></element-citation></ref>
<ref id="b3-br-03-01-0055"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinchey</surname><given-names>J</given-names></name><name><surname>Chaves</surname><given-names>C</given-names></name><name><surname>Appignani</surname><given-names>B</given-names></name><etal/></person-group><article-title>A reversible posterior leukoencephalopathy syndrome</article-title><source>N Engl J Med</source><volume>334</volume><fpage>494</fpage><lpage>500</lpage><year>1996</year></element-citation></ref>
<ref id="b4-br-03-01-0055"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Hataya</surname><given-names>H</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Anbo</surname><given-names>K</given-names></name></person-group><article-title>Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome</article-title><source>Am J Kidney Dis</source><volume>37</volume><fpage>E30</fpage><year>2001</year></element-citation></ref>
<ref id="b5-br-03-01-0055"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsumi</surname><given-names>K</given-names></name><name><surname>Amemiya</surname><given-names>S</given-names></name><name><surname>Lizuka</surname><given-names>M</given-names></name><name><surname>Lino</surname><given-names>Y</given-names></name><name><surname>Katayama</surname><given-names>Y</given-names></name></person-group><article-title>Acute posterior leukoencephalopathy in a patient with nephrotic syndrome</article-title><source>Clin Exp Nephrol</source><volume>7</volume><fpage>63</fpage><lpage>66</lpage><year>2003</year></element-citation></ref>
<ref id="b6-br-03-01-0055"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x00FC;m&#x00FC;&#x015F;</surname><given-names>H</given-names></name><name><surname>Per</surname><given-names>H</given-names></name><name><surname>Kumanda&#x015F;</surname><given-names>S</given-names></name><name><surname>Yikilmaz</surname><given-names>A</given-names></name></person-group><article-title>Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature</article-title><source>Neurol Sci</source><volume>31</volume><fpage>125</fpage><lpage>131</lpage><year>2010</year></element-citation></ref>
<ref id="b7-br-03-01-0055"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>JR</given-names></name><name><surname>Ding</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis</article-title><source>Intern Med</source><volume>47</volume><fpage>867</fpage><lpage>875</lpage><year>2008</year></element-citation></ref>
<ref id="b8-br-03-01-0055"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>CJ</given-names></name><name><surname>Seith</surname><given-names>A</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome (PRES)</article-title><source>Indian Pediatr</source><volume>43</volume><fpage>657</fpage><lpage>658</lpage><year>2006</year></element-citation></ref>
<ref id="b9-br-03-01-0055"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>VH</given-names></name><name><surname>Wijdicks</surname><given-names>EF</given-names></name><name><surname>Manno</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title><source>Arch Neurol</source><volume>65</volume><fpage>205</fpage><lpage>210</lpage><year>2008</year></element-citation></ref>
<ref id="b10-br-03-01-0055"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartynski</surname><given-names>WS</given-names></name><name><surname>Boardman</surname><given-names>JF</given-names></name></person-group><article-title>Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome</article-title><source>AJNR Am J Neuroradiol</source><volume>28</volume><fpage>1320</fpage><lpage>1327</lpage><year>2007</year></element-citation></ref>
<ref id="b11-br-03-01-0055"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekhar</surname><given-names>A</given-names></name><name><surname>George</surname><given-names>TJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature</article-title><source>Oncologist</source><volume>12</volume><fpage>1332</fpage><lpage>1335</lpage><year>2007</year></element-citation></ref>
<ref id="b12-br-03-01-0055"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>VL</given-names></name><name><surname>Hurrell</surname><given-names>MA</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name></person-group><article-title>Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed</article-title><source>Intern Med J</source><volume>35</volume><fpage>83</fpage><lpage>90</lpage><year>2005</year></element-citation></ref>
<ref id="b13-br-03-01-0055"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>A</given-names></name><name><surname>Hayakawa</surname><given-names>K</given-names></name><name><surname>Houjyou</surname><given-names>M</given-names></name></person-group><article-title>CT and MRI findings of cyclosporine-related encephalopathy and hypertensive encephalopathy</article-title><source>Pediatr Radiol</source><volume>32</volume><fpage>340</fpage><lpage>343</lpage><year>2002</year></element-citation></ref>
<ref id="b14-br-03-01-0055"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinohs</surname><given-names>M</given-names></name><name><surname>Straube</surname><given-names>T</given-names></name><name><surname>Baum</surname><given-names>P</given-names></name><name><surname>Berrouschot</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name></person-group><article-title>Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus</article-title><source>J Neurol</source><volume>249</volume><fpage>780</fpage><lpage>781</lpage><year>2002</year></element-citation></ref>
<ref id="b15-br-03-01-0055"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>A</given-names></name><name><surname>Farooq</surname><given-names>MU</given-names></name><name><surname>Majid</surname><given-names>A</given-names></name><name><surname>Kassab</surname><given-names>M</given-names></name></person-group><article-title>Chemotherapy-related posterior reversible leukoencephalopathy syndrome</article-title><source>Nat Clin Pract Neurol</source><volume>5</volume><fpage>163</fpage><lpage>169</lpage><year>2009</year></element-citation></ref>
<ref id="b16-br-03-01-0055"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikura</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome</article-title><source>Nephrol</source><volume>Dial Transplant 23</volume><fpage>2531</fpage><lpage>2536</lpage><year>2008</year></element-citation></ref>
<ref id="b17-br-03-01-0055"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fugate</surname><given-names>JE</given-names></name><name><surname>Claassen</surname><given-names>DO</given-names></name><name><surname>Cloft</surname><given-names>HJ</given-names></name><name><surname>Kallmes</surname><given-names>DF</given-names></name><name><surname>Kozak</surname><given-names>OS</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings</article-title><source>Mayo Clin Proc</source><volume>85</volume><fpage>427</fpage><lpage>432</lpage><year>2010</year></element-citation></ref>
<ref id="b18-br-03-01-0055"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlakis</surname><given-names>SG</given-names></name><name><surname>Frank</surname><given-names>Y</given-names></name><name><surname>Kalina</surname><given-names>P</given-names></name><etal/></person-group><article-title>Occipital-parietal encephalopathy: a new name for an old syndrome</article-title><source>Pediatr Neurol</source><volume>16</volume><fpage>145</fpage><lpage>148</lpage><year>1997</year></element-citation></ref>
<ref id="b19-br-03-01-0055"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>RK</given-names></name></person-group><article-title>Posterior leukoencephalopathy syndrome</article-title><source>Postgrad Med J</source><volume>77</volume><fpage>24</fpage><lpage>28</lpage><year>2001</year></element-citation></ref>
<ref id="b20-br-03-01-0055"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>RB</given-names></name></person-group><article-title>Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions</article-title><source>Neurologist</source><volume>8</volume><fpage>22</fpage><lpage>34</lpage><year>2002</year></element-citation></ref>
<ref id="b21-br-03-01-0055"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Koo</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>Clinical spectrum of reversible posterior leukoencephalopathy syndrome</article-title><source>Pediatr Neurol</source><volume>24</volume><fpage>361</fpage><lpage>364</lpage><year>2001</year></element-citation></ref>
<ref id="b22-br-03-01-0055"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Bonham</surname><given-names>A</given-names></name><name><surname>Fukui</surname><given-names>M</given-names></name></person-group><article-title>Immunosuppressive-associated leukoencephalopathy in organ transplant recipients</article-title><source>Transplantation</source><volume>69</volume><fpage>467</fpage><lpage>472</lpage><year>2000</year></element-citation></ref>
<ref id="b23-br-03-01-0055"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijtenbeek</surname><given-names>JM</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name><name><surname>Vecht</surname><given-names>CJ</given-names></name></person-group><article-title>Cyclosporine neurotoxicity: a review</article-title><source>J Neurol</source><volume>246</volume><fpage>339</fpage><lpage>346</lpage><year>1999</year></element-citation></ref>
<ref id="b24-br-03-01-0055"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truwit</surname><given-names>CL</given-names></name><name><surname>Denaro</surname><given-names>CP</given-names></name><name><surname>Lake</surname><given-names>JR</given-names></name><name><surname>DeMareo</surname><given-names>T</given-names></name></person-group><article-title>MR imaging of reversible cyclosporine A-induced neurotoxicity</article-title><source>AJNR Am J Neuroradiol</source><volume>12</volume><fpage>651</fpage><lpage>659</lpage><year>1991</year></element-citation></ref>
<ref id="b25-br-03-01-0055"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlasveld</surname><given-names>LT</given-names></name><name><surname>Cornelissen</surname><given-names>JJ</given-names></name><name><surname>Dellemijn</surname><given-names>PL</given-names></name><name><surname>Joosse</surname><given-names>MV</given-names></name><name><surname>van den Bent</surname><given-names>MJ</given-names></name></person-group><article-title>Cortical blindness during treatment with cyclosporine</article-title><source>Ned Tijdschr Geneeskd</source><volume>138</volume><fpage>2057</fpage><lpage>2061</lpage><year>1994</year><comment>(In Dutch)</comment></element-citation></ref>
<ref id="b26-br-03-01-0055"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>RK</given-names></name></person-group><article-title>Posterior leukoencephalopathy syndrome</article-title><source>Postgrad Med J</source><volume>77</volume><fpage>24</fpage><lpage>28</lpage><year>2001</year></element-citation></ref>
<ref id="b27-br-03-01-0055"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>RB</given-names></name><name><surname>Bravo</surname><given-names>SM</given-names></name><name><surname>Klufas</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases</article-title><source>AJR AM J Roentgennol</source><volume>165</volume><fpage>627</fpage><lpage>631</lpage><year>1995</year></element-citation></ref>
<ref id="b28-br-03-01-0055"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamano</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Posterior reversible encephalopathy syndrome following measles vaccination</article-title><source>J Neurol Sci</source><volume>298</volume><fpage>124</fpage><lpage>126</lpage><year>2010</year></element-citation></ref>
<ref id="b29-br-03-01-0055"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebora</surname><given-names>AE</given-names></name><name><surname>Regesta</surname><given-names>G</given-names></name></person-group><article-title>Reversible posterior leukoencephalopathy: a possible threat for psoriatic patients treated with biological agents</article-title><source>J Eur Acad Dermatol Venereol</source><volume>24</volume><fpage>97</fpage><lpage>98</lpage><year>2010</year></element-citation></ref>
<ref id="b30-br-03-01-0055"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavragni</surname><given-names>CP</given-names></name><name><surname>Vhchoyiannopoulos</surname><given-names>PC</given-names></name><name><surname>Kosmas</surname><given-names>N</given-names></name><etal/></person-group><article-title>A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion</article-title><source>Rheumatology (Oxford)</source><volume>43</volume><fpage>1450</fpage><lpage>1451</lpage><year>2004</year></element-citation></ref>
<ref id="b31-br-03-01-0055"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Rajam</surname><given-names>L</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome (PRES&#x002F;RPLS) during pulse steroid therapy in macrophage activation syndrome</article-title><source>Indian J Pediatr</source><volume>78</volume><fpage>1002</fpage><lpage>1004</lpage><year>2011</year></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-br-03-01-0055" position="float">
<label>Figure 1</label>
<caption><p>MRI axial T2WI image revealing cortical and subcortical hyper-intensities at the parieto-occipital regions (left two pictures) and MRA with display of the circle of Willis revealing the slender posterior cerebral artery (right picture). MRI, magnetic resonance imaging; T2WI, T2-weighted image; MRA, magnetic resonance angiography.</p></caption>
<graphic xlink:href="br-03-01-0055-g00.tif"/>
</fig>
<fig id="f2-br-03-01-0055" position="float">
<label>Figure 2</label>
<caption><p>MRI scans obtained 2 weeks after onset. The previously existed hyper-intensity signal in the axial T2WI image had disappeared (left two pictures), MRA with display of the circle of wills revealing the slender posterior cerebral artery as before (right picture). MRI, magnetic resonance imaging; T2WI, T2-weighted image; MRA, magnetic resonance angiography.</p></caption>
<graphic xlink:href="br-03-01-0055-g01.tif"/>
</fig>
</floats-group>
</article>